logo
AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets

AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets

Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets
MOUNTAIN VIEW, CA / ACCESS Newswire / June 16, 2025 / AbTherx, a biotechnology company with innovative technologies that enable therapeutic antibody discovery against challenging targets, today announced a research collaboration with GPCR Therapeutics, a clinical-stage biopharmaceutical company, to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets.
AbTherx's antibody discovery platform is built on two decades of experience and utilizes the immune system's evolutionary intelligence to identify diverse and developable human antibodies. This collaboration leverages AbTherx's innovative, patent-pending Atlas Long CDR3 Mouse to create antibodies with long CDR3 regions, providing the unique opportunity to access buried epitopes within GPCRs, ion channels, and other difficult targets. These fully human antibodies minimize developability and immunogenicity risk by leveraging a rare, naturally occurring phenomenon in humans.
GPCR Therapeutics is developing drugs targeting GPCRs to treat cancer, fibrosis, and obesity. Its stem cell mobilization program is now undergoing a phase 2 clinical trial in the United States of America. The company has also established capabilities for antigen development, antibody screening, and profiling for the discovery of antibodies targeting GPCRs, which are historically known to be challenging targets for antibody discovery.
'We are excited to strategically partner with GPCR Therapeutics to co-create a potentially life-saving therapeutic, leveraging the full power of the AbTherx team, combining a potentially best-in-class antibody discovery platform with a highly successful team of drug hunters,' said Justin Mika, CEO of AbTherx. 'This collaboration is a first for our proprietary Atlas Long CDR3 Mouse. We are keen to explore the full potential of this technology to discover and develop transformative, new antibody therapies for challenging targets.'
'We are thrilled to collaborate with one of the world's most experienced antibody discovery teams,' said Dong Seung Seen, CEO of GPCR Therapeutics. 'Our partnership with AbTherx marks a significant milestone for GPCR Therapeutics, strategically enhancing our ability to generate therapeutic antibodies against our priority targets. By combining our respective strengths, we aim to explore the largely uncharted territory of GPCR-targeting antibodies, ultimately striving to bring multiple first-in-class therapies to patients. The potential to expand our focus to additional targets in oncology, fibrosis, and obesity, further underscores the strategic value of this collaboration.'
AbTherx has a range of partnering strategies from technology licensing to strategic collaborations. The Long CDR3 technology has the potential to deliver high-impact therapeutics for some of the most challenging targets. It is available for strategic research collaborations and co-development partnerships aimed at advancing innovative therapeutics. This AbTherx and GPCR Therapeutics partnership is expected to yield a pre-clinical asset governed by a 50/50 ownership structure, drawing on the complementary strengths and resources of both parties to develop a novel modality targeting GPCRs, the largest and most diverse family of drug targets.
About AbTherx
AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit www.abtherx.com.
About GPCR Therapeutics
GPCR Therapeutics, Inc. is a clinical-stage biopharmaceutical company taking an innovative approach to developing therapeutics based on its proprietary GPCR science. The company is currently conducting a Phase 2 clinical trial in the U.S. to evaluate the efficacy of GPC-100 in combination with propranolol in patients with multiple myeloma, in collaboration with Exicure. In addition to its lead program, GPCR Therapeutics is advancing multiple partnerships with pharmaceutical and biotech companies to develop therapies targeting cancer, fibrosis, obesity, and rare diseases. The company is headquartered in Seoul, South Korea. For more information, please visit www.gpcr.co.kr
AbTherx Media Contact
Stacey Borders
[email protected]
SOURCE: AbTherx, Inc
press release
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NVDA: Top Analysts Lift Nvidia Targets Ahead of Earnings -- Can AI Boom Deliver?
NVDA: Top Analysts Lift Nvidia Targets Ahead of Earnings -- Can AI Boom Deliver?

Yahoo

time16 minutes ago

  • Yahoo

NVDA: Top Analysts Lift Nvidia Targets Ahead of Earnings -- Can AI Boom Deliver?

This article first appeared on GuruFocus. Aug 21 - Nvidia (NASDAQ:NVDA) continues to draw investor attention as analysts raise their price targets ahead of the company's second-quarter earnings report on August 27. The chipmaker's stock outlook remains supported by strong AI demand, its leadership position in the semiconductor market, and easing U.S. export restrictions. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Is NVDA fairly valued? Test your thesis with our free DCF calculator. Shares of NVDA edged higher on Thursday's opening. Consensus estimates call for earnings of $1.01 per share on revenue of $45.87 billion. Analysts remain confident that Nvidia will deliver another solid quarter, although expectations are high. KeyBanc analyst John Vinh increased his price target on NVDA to $215 from $190 while reiterating a Buy rating. Vinh expects strong July-quarter results but noted guidance for the October quarter could be more cautious, as forecasts likely exclude China sales pending license approvals. If those sales are included, Nvidia could generate an additional $2 billion to $3 billion from its H20 and RTX6000D chips. Susquehanna analyst Christopher Rolland also lifted his target, moving to $210 from $180 with a Buy rating. Rolland cited the strength of Nvidia's data center segment and highlighted the upcoming GB300 product line as a catalyst for double-digit revenue growth, supported by higher selling prices and expanding margins. Sign in to access your portfolio

CAVA Group, Inc. (CAVA) 'Just Costs Too Much,' Says Jim Cramer
CAVA Group, Inc. (CAVA) 'Just Costs Too Much,' Says Jim Cramer

Yahoo

time16 minutes ago

  • Yahoo

CAVA Group, Inc. (CAVA) 'Just Costs Too Much,' Says Jim Cramer

We recently published . CAVA Group, Inc. (NYSE:CAVA) is one of the stocks Jim Cramer recently discussed. CAVA Group, Inc. (NYSE:CAVA)'s shares are among the worst performers on the market as they have lost 40% year-to-date. The stock fell by 16.6% in August after the firm's second quarter earnings report saw its revenue miss estimates by $5 million, and it slashed its full-year midpoint same-store sales guidance to 5% from an earlier 7%. Cramer remarked that one reason CAVA Group, Inc. (NYSE:CAVA) is suffering because its prices are too high: '[On recent earnings] Yeah and I do think that when we look at Cava, not mentioned on the call, it's expensive. You're talking about 15 smackers versus go and get a smash burger a couple of drinks, a diet coke. Yeah but Chilli's is ten dollars. Photo by Syed Ahmad on Unsplash Later during the day, Cramer commented on CAVA Group, Inc. (NYSE:CAVA)'s pricing in detail: 'Brett Schulman, who's a very perceptive man, the CEO of CAVA said, 'We have a fluid… macroeconomic climate.' He told Restaurant Business, which is an excellent trade publication, that the macro climate was like a fog, a fog that the consumer's trying to find her way through… He goes on to say, 'I think the consumer is less firm-footed, less ebullient than they were last year… To me, it's pretty clear what's going on. CAVA and Sweetgreen have to lower their prices or give us a couple of much lower-priced dishes if they want to turn things around. For now, they're pricing themselves out of this American market. I get why they're reluctant to cut prices. What business wants to lower margins?… While we acknowledge the potential of CAVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Deere (DE) Upgraded by Oppenheimer as Robotics Expansion Strengthens Growth Outlook
Deere (DE) Upgraded by Oppenheimer as Robotics Expansion Strengthens Growth Outlook

Yahoo

time16 minutes ago

  • Yahoo

Deere (DE) Upgraded by Oppenheimer as Robotics Expansion Strengthens Growth Outlook

Deere & Company (NYSE:DE) ranks among the . Following the company's fiscal third-quarter results, Oppenheimer maintained its Outperform rating on Deere & Company (NYSE:DE) and increased its price target from $560 to $566 on August 15. The change follows a 6.8% stock selloff sparked by Deere's quarterly report, which Oppenheimer described as offering investors an alluring entry position as positive signals appear in the markets of Europe and Latin America. Although the end-of-period results were characterized as 'anticipated and better-than-feared,' Oppenheimer pointed out that pessimistic comments to the report were centered on poor end-of-period results, unanticipated negative pricing in Large Agriculture, and increasing tariff expenses. With projections of modest increase led by North American harvest results, clarity on biofuels policy, and performance in used equipment merchandising, the firm maintained expectations at the higher range of the 2026 consensus. Deere & Company (NYSE:DE) is an American company that manufactures agricultural, heavy, and forestry machinery, diesel engines, heavy equipment drivetrains, and lawn care equipment. The company also provides financial services and engages in other business operations. With its AI-powered autonomous tractors, harvesters, sprayers, and other machinery, the company has began venturing into agricultural robotics. One notable instance is the company's See and Spray robots, which are used to spray herbicides and fertilizers. While we acknowledge the potential of DE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DE and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store